Loading...

Please Note

  • An estimate based on public data for similar roles. Not provided by the employer.

製造拠点ファイナンス担当

Japan Astellas Pharmaceutical Estimated salary: ¥7,000,000–¥12,000,000 per year
Role summary

Written by MyIslandJob from the job title and employer. See the employer's page for the full description.

This role supports finance activities at an Astellas manufacturing site, partnering with plant leadership and operations teams on budgeting, forecasting, cost control, management reporting, and financial analysis. Candidates are expected to have experience in accounting, controlling, financial planning, or business partnering, ideally within manufacturing or the pharmaceutical industry. Strong Excel and financial systems skills, attention to detail, business judgment, and the ability to explain financial information clearly are important. Japanese and English communication skills may be required for collaboration with local and global stakeholders. The successful candidate should be proactive, commercially minded, compliant with company policies, and comfortable challenging assumptions while supporting sound operational and investment decisions.

About the employer

Astellas Pharma Inc. is a Japan-based global pharmaceutical company headquartered in Tokyo. Established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas researches, develops, manufactures, and commercializes prescription medicines worldwide. Its principal focus areas include oncology, immunology, neuroscience, rare diseases, and other conditions with significant unmet medical needs. The company operates research, manufacturing, and commercial organizations across Japan and international markets, working with healthcare professionals, research institutions, and technology partners. Astellas emphasizes scientific innovation, patient-centered drug development, responsible business conduct, and collaboration across global teams. Its manufacturing and finance functions support reliable product supply, efficient operations, regulatory compliance, and long-term investment in new medicines.

Loading...